5 unknown, 3 not yet recruiting, 2 recruiting, 1 terminated. 5 Phase 2, 4 Phase 1, 2 Phase 4, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Unknown 3, Terminated 1 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Relapsed or Refractory B-cell Lymphoma: new trials by email Literature Review of Relapsed or Refractory B-cell Lymphoma trials Research Report on Relapsed or Refractory B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Glofitamab, Epcoritamab, Polatuzumab Vedotin - Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 40 | 2026-09-01 | 2026-10-20 |
| Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma Pirtobrutinib, Second Infusion of Commercial Anti-CD19 CAR-T Cells - Relapsed or Refractory B-cell Lymphoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 20 | 2026-06-01 | 2026-06-03 |
| Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL SR-GDP - Relapsed or Refractory B-cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 50 | 2023-10-30 | 2023-11-07 |
| JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma infusion of JY231 injection - Relapsed or Refractory B-cell Lymphoma | Early Phase 1 | Unknown | Guangdong Second Provincial General Hospital | 20 | 2023-08-18 | 2023-09-21 |
| A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma Relmacabtagene Autoleucel Injection - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Not yet recruiting | Changhai Hospital | 13 | 2023-06-20 | 2023-06-15 |
| Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma Relma-cel - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Recruiting | Ruijin Hospital | 8 | 2023-05-01 | 2024-10-23 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma RGV004 - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2022-02-08 | 2023-02-06 |
| Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma Recombinant Anti-CD19m-CD3 Antibody Injection - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | EVIVE Biotechnology | 54 | 2019-09-15 | 2019-08-14 |
| Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | Peking University | 20 | 2017-06-21 | 2017-09-14 |
| CART-19 Cells for R/R B-cell Lymphoma CART-19 cells - Relapsed or Refractory B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Fujian Medical University | 20 | 2016-01-01 | 2018-01-05 |
Lymphoma, B-Cell (11) · Recurrence (11) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Disease Attributes (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma, Non-Hodgkin (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Lymphoma (9) · Chronic Disease (1) · Hematologic Diseases (1) · Leukemia (1)
relmacabtagene autoleucel (2) · Cyclophosphamide (1) · fludarabine (1) · gemcitabine-oxaliplatin regimen (1) · glofitamab (1) · obinutuzumab (1) · pirtobrutinib (1) · polatuzumab vedotin (1)
Ruijin Hospital (2) · Changhai Hospital (1) · EVIVE Biotechnology (1) · Fujian Medical University (1) · Guangdong Second Provincial General Hospital (1) · MingSight Pharmaceuticals, Inc (1) · National Research Center for Hematology, Russia (1) · Peking University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sun Yat-sen University (1)
China (8) · Russia (1)
Elena Parovichnikova, MD, DSc (1) · Jun Zhu, MD (1) · Li Chen (1) · Qing Zhang, Doctoral (1) · Song Yuqin, Doctor (1) · Weili Zhao, PhD, MD (1) · Wenbin Qian (1) · Xiaoyu Xiang, PhD (1) · Zhitao Ying, MD (1)